6653-96-9

Usage

Uses

Due to the limited information available on Imidazo[1,2-b]pyridazin-6-amine, it is challenging to list specific applications for Imidazo[1,2-b]pyridazin-6-amine. However, based on its chemical structure, it may have potential uses in various industries, such as pharmaceuticals, materials science, or chemical research. To better understand its potential applications, further research and development are required. Once more information is available, the following structure can be used to list its uses:
Used in [Application Industry]:
Imidazo[1,2-b]pyridazin-6-amine is used as [application type] for [application reason].

InChI:InChI=1/C6H6N4/c7-5-1-2-6-8-3-4-10(6)9-5/h1-4H,(H2,7,9)

Upstream product

• 13493-79-3 C₆H₄ClN₃*ClH 
• 6775-78-6 6-chloroimidazo[1,2-b]pyridazine 
• 13526-73-3 6-azido-imidazo[1,2-b]pyridazine 

Downstream Products

• 316352-04-2 6-(phthalimidoacetyl)aminoimidazo[1,2-b]pyridazine 
• 316352-03-1 6-N'-methylureidoimidazo[1,2-b]pyridazine 
• 159045-51-9 6-ureidoimidazo[1,2-b]pyridazine 
• 159045-44-0 3-(6-aminoimidazo[1,2-b]pyridazinium-1-yl)methyl-7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-methoxymethoxyiminoacetamido]-3-cephem-4-carboxylate 
• 166176-43-8 6-(tert-butoxycarbonylaminoacetyl)aminoimidazo[1,2-b]pyridazine 
• 316352-11-1 C₂₂H₂₃N₁₁O₇S₂ 
• 159045-46-2 C₂₁H₂₁N₁₁O₇S₂ 
• 316352-12-2 C₂₇H₃₁N₁₁O₉S₂ 

Relevant academic research and scientific papers

Mild and highly selective palladium-catalyzed monoarylation of ammonia enabled by the use of bulky biarylphosphine ligands and palladacycle precatalysts

A method for the Pd-catalyzed arylation of ammonia with a wide range of aryl and heteroaryl halides, including challenging five-membered heterocyclic substrates, is described. Excellent selectivity for monoarylation of ammonia to primary arylamines was achieved under mild conditions or at rt by the use of bulky biarylphosphine ligands (L6, L7, and L4) as well as their corresponding aminobiphenyl palladacycle precatalysts (3a, 3b, and 3c). As this process requires neither the use of a glovebox nor high pressures of ammonia, it should be widely applicable.

Studies on Anti-MRSA parenteral cephalosporins I. Synthesis and antibacterial activity of 7

In order to improve the antibacterial activity of cefozopran (CZOP) against methicillin-resistant Staphylococcus aureus (MRSA), we initiated chemical modification to introduce a 2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyimino acetyl group at the C-7 position and a 3- or 6-substituted imidazo[1,2-b]pyridazinium or 5-substituted imidazo[1,2-a]pyridinium group at the C-3' position. Although this approach successfully enhanced the anti-MRSA activity of CZOP two to eight times, a slight decrease in the activity against Gram-negative bacteria including Pseudomonas aeruginosa was involved. Among the novel derivatives, 3-(6-aminoimidazo [1,2-b]pyridazinium-1-yl) methyl-7β-[2-(5-amino -1,2,4-thiadiazol-3-yl) -2(Z)-hydroxyiminoacetamidol]-3-cephem-4-carboxylate (44a) showed an excellent balance of activity against MRSA and Gram-negative bacteria.

Cephem compounds, their production and use

Novel cephem compounds of the general formula: STR1 wherein R1 is a lower alkyl group, and salts and esters thereof, showing excellent and balanced antibacterial activity against a broad spectrum of bacteria, especially by rectal administration, and their production and use as antimicrobial agents are described.